S. Parthasarathi, P. Ramesh, P. Sathyan, Prajnya Ray
{"title":"Netarsudil相关可逆性“蜂窝”型角膜上皮水肿","authors":"S. Parthasarathi, P. Ramesh, P. Sathyan, Prajnya Ray","doi":"10.4103/jcor.jcor_12_22","DOIUrl":null,"url":null,"abstract":"Netarsudil (Rho-associated protein kinase inhibitor) is one of the newer anti-glaucoma medications used for the management of glaucoma. It has the most common side effects, such as conjunctival hyperemia, subconjunctival hemorrhage, and cornea verticillata. This manuscript focuses on a rarer side effect of netarsudil-associated reticular corneal epithelial edema, after netarsudil application for 3 months in a 62-year-old male. This side effect is rarely reported in the literature. In this manuscript, netarsudil-associated reversible corneal epithelial edema and its management have been reported.","PeriodicalId":33073,"journal":{"name":"Journal of Clinical Ophthalmology and Research","volume":"11 1","pages":"62 - 64"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Netarsudil-associated reversible “honeycomb” pattern corneal epithelial edema\",\"authors\":\"S. Parthasarathi, P. Ramesh, P. Sathyan, Prajnya Ray\",\"doi\":\"10.4103/jcor.jcor_12_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Netarsudil (Rho-associated protein kinase inhibitor) is one of the newer anti-glaucoma medications used for the management of glaucoma. It has the most common side effects, such as conjunctival hyperemia, subconjunctival hemorrhage, and cornea verticillata. This manuscript focuses on a rarer side effect of netarsudil-associated reticular corneal epithelial edema, after netarsudil application for 3 months in a 62-year-old male. This side effect is rarely reported in the literature. In this manuscript, netarsudil-associated reversible corneal epithelial edema and its management have been reported.\",\"PeriodicalId\":33073,\"journal\":{\"name\":\"Journal of Clinical Ophthalmology and Research\",\"volume\":\"11 1\",\"pages\":\"62 - 64\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Ophthalmology and Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jcor.jcor_12_22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Ophthalmology and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcor.jcor_12_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Netarsudil (Rho-associated protein kinase inhibitor) is one of the newer anti-glaucoma medications used for the management of glaucoma. It has the most common side effects, such as conjunctival hyperemia, subconjunctival hemorrhage, and cornea verticillata. This manuscript focuses on a rarer side effect of netarsudil-associated reticular corneal epithelial edema, after netarsudil application for 3 months in a 62-year-old male. This side effect is rarely reported in the literature. In this manuscript, netarsudil-associated reversible corneal epithelial edema and its management have been reported.